Britain’s state-run National Health Service will on Sept. 13 begin the world’s biggest trial of Grail Inc.’s flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear.
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.
What if you could detect cancer just as it is getting started? New research published in the journal Nature just might give medicine the tools to do just that.
South San Francisco-based Veracyte entered a multi-year partnership with AstraZeneca’s hematology research and development unit, Acerta Pharma.
Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.